Exelixis
EXEL
#2109
Rank
โ‚น632.25 B
Marketcap
โ‚น2,216
Share price
-1.53%
Change (1 day)
23.95%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Cash on Hand

Cash on Hand as of June 2024 : โ‚น84.06 B

According to Exelixis's latest financial reports the company has โ‚น84.06 B in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Exelixis - Cash on Hand chart (from 2000 to 2024)

Cash on Hand by year

Year Cash on Hand Change
2023-12-31โ‚น82.85 B-23.48%
2022-12-31โ‚น108.27 B-0.96%
2021-12-31โ‚น109.33 B24.11%
2020-12-31โ‚น88.09 B45.21%
2019-12-31โ‚น60.66 B25.78%
2018-12-31โ‚น48.22 B94.79%
2017-12-31โ‚น24.75 B-13.21%
2016-12-31โ‚น28.52 B157%
2015-12-31โ‚น11.10 B21.57%
2014-12-31โ‚น9.13 B-39.06%
2013-12-31โ‚น14.98 B-33.5%
2012-12-31โ‚น22.53 B119.25%
2011-12-31โ‚น10.27 B40.92%
2010-12-31โ‚น7.29 B-22.91%
2009-12-31โ‚น9.45 B-27.48%
2008-12-31โ‚น13.04 B21.83%
2007-12-31โ‚น10.70 B35.15%
2006-12-31โ‚น7.92 B18.45%
2005-12-31โ‚น6.68 B9.59%
2004-12-31โ‚น6.10 B-43.57%
2003-12-31โ‚น10.81 B1.59%
2002-12-31โ‚น10.64 B-3.11%
2001-12-31โ‚น10.98 B109.15%
2000-12-31โ‚น5.25 B1651.22%
1999-12-31โ‚น0.29 B

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
โ‚น316.63 B 276.67%๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚น611.09 B 626.96%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚น952.53 B 1,033.13%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น558.14 B 563.97%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น780.29 B 828.24%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น2.137 T 2,442.42%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น595.73 B 608.68%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น2.37 B-97.17%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น6.49 B-92.28%๐Ÿ‡บ๐Ÿ‡ธ USA